S Vauléon

402 total citations
9 papers, 319 citations indexed

About

S Vauléon is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, S Vauléon has authored 9 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in S Vauléon's work include Iron Metabolism and Disorders (4 papers), Hemoglobinopathies and Related Disorders (3 papers) and RNA modifications and cancer (2 papers). S Vauléon is often cited by papers focused on Iron Metabolism and Disorders (4 papers), Hemoglobinopathies and Related Disorders (3 papers) and RNA modifications and cancer (2 papers). S Vauléon collaborates with scholars based in Netherlands, United Kingdom and Italy. S Vauléon's co-authors include Kai Riecke, Luciana Summo, Frank Schwoebel, Stefan Zöllner, Dorine W. Swinkels, Malcolm Boyce, Steve Warrington, Coby M. Laarakkers, Lucas T. van Eijk and Matthijs Kox and has published in prestigious journals such as Blood, British Journal of Pharmacology and Critical Care.

In The Last Decade

S Vauléon

9 papers receiving 306 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Vauléon Netherlands 8 148 111 104 66 57 9 319
Florence Zylbersztejn France 8 55 0.4× 79 0.7× 35 0.3× 30 0.5× 18 0.3× 8 153
Shi Chen United States 9 99 0.7× 286 2.6× 56 0.5× 75 1.1× 46 0.8× 16 361
Zhenqing Xie China 6 128 0.9× 282 2.5× 30 0.3× 74 1.1× 18 0.3× 10 354
Ruzhica Bogeska Germany 6 139 0.9× 108 1.0× 86 0.8× 25 0.4× 58 1.0× 8 235
Matthew A. Loberg United States 9 186 1.3× 159 1.4× 68 0.7× 22 0.3× 104 1.8× 16 335
Shawn Sarkaria United States 6 103 0.7× 164 1.5× 55 0.5× 37 0.6× 24 0.4× 9 239
Amritha Varshini Hanasoge Somasundara United States 5 59 0.4× 95 0.9× 50 0.5× 40 0.6× 18 0.3× 6 168
Stéphane M. Camus France 8 40 0.3× 159 1.4× 60 0.6× 19 0.3× 31 0.5× 10 279
Fatemeh Alikarami‬ Iran 9 28 0.2× 107 1.0× 30 0.3× 32 0.5× 12 0.2× 15 179
Michela Carlet Germany 8 71 0.5× 137 1.2× 15 0.1× 49 0.7× 47 0.8× 14 219

Countries citing papers authored by S Vauléon

Since Specialization
Citations

This map shows the geographic impact of S Vauléon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Vauléon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Vauléon more than expected).

Fields of papers citing papers by S Vauléon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Vauléon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Vauléon. The network helps show where S Vauléon may publish in the future.

Co-authorship network of co-authors of S Vauléon

This figure shows the co-authorship network connecting the top 25 collaborators of S Vauléon. A scholar is included among the top collaborators of S Vauléon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Vauléon. S Vauléon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Steurer, Michael, Marco Montillo, Lydia Scarfò, et al.. (2019). Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 104(10). 2053–2060. 69 indexed citations
2.
Ludwig, Heinz, Katja Weisel, Maria Teresa Petrucci, et al.. (2017). Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Leukemia. 31(4). 997–1000. 60 indexed citations
3.
Boyce, Malcolm, Steve Warrington, Stefan Zöllner, et al.. (2016). Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects. British Journal of Pharmacology. 173(10). 1580–1588. 68 indexed citations
4.
Macdougall, Iain C., et al.. (2015). FP660PHARMACOKINETICS AND PHARMACODYNAMICS OF LEXAPTEPID, A NOVEL ANTI-HEPCIDIN MOLECULE, IN ESA-RESISTANT HAEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation. 30(suppl_3). iii294–iii295. 7 indexed citations
5.
Hoehlig, Kai, Kirk W. Johnson, Evgeny Pryazhnikov, et al.. (2015). A novel CGRP‐neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation. British Journal of Pharmacology. 172(12). 3086–3098. 15 indexed citations
6.
Eijk, Lucas T. van, Frank Schwoebel, Luciana Summo, et al.. (2014). Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 124(17). 2643–2646. 79 indexed citations
7.
8.
Gobbi, Marco, Federico Caligaris‐Cappio, Marco Montillo, et al.. (2012). Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood. 120(21). 4593–4593. 3 indexed citations
9.
Riecke, Kai, Stefan Zöllner, Malcolm Boyce, et al.. (2012). Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.. Blood. 120(21). 2342–2342. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Zylbersztejn Breakdown of academic impact, for papers by Shi Chen Breakdown of academic impact, for papers by Zhenqing Xie Breakdown of academic impact, for papers by Ruzhica Bogeska Breakdown of academic impact, for papers by Matthew A. Loberg Breakdown of academic impact, for papers by Shawn Sarkaria Breakdown of academic impact, for papers by Amritha Varshini Hanasoge Somasundara Breakdown of academic impact, for papers by Stéphane M. Camus Breakdown of academic impact, for papers by Fatemeh Alikarami‬ Breakdown of academic impact, for papers by Michela Carlet
Rankless by CCL
2026